Huatai (06886) has completed the issuance of zero-coupon convertible bonds with a total amount of 10 billion Hong Kong dollars maturing in 2027.
Huatai Securities (06886) announced that all preconditions under the subscription agreement have been met, and a total of HK$10 billion in bonds have been issued on February 10, 2026. According to the terms and conditions, the bonds can be converted into H-shares under certain circumstances, with an initial conversion price of HK$19.70 per H-share (adjustable), and assuming full conversion at the initial conversion price of HK$19.70 per H-share, the bonds can be converted into approximately 508 million H-shares.
Huatai (06886) announced that all the preconditions under the subscription agreement have been met, and a total of HK$10 billion in bonds were issued on February 10, 2026. According to the terms and conditions, the bonds can be converted into H shares under certain circumstances, with an initial conversion price of HK$19.70 per H share (adjustable). Assuming all the bonds are converted at the initial conversion price of HK$19.70 per H share, the bonds can be converted into approximately 508 million H shares.
The total principal amount of the bonds is HK$10 billion, and the net proceeds from the bond issuance is approximately HK$9.247 billion. The company plans to use the proceeds from the bond issuance to support the overseas business development, particularly in fixed income, foreign exchange, and commodities sales and trading businesses, wealth management, and asset management businesses (representing about 90% of the net proceeds from the bond issuance), as well as to supplement other operating funds to ensure liquidity and financial stability through mainly allocating deposits and other high liquidity assets (representing about 10% of the net proceeds from the bond issuance).
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Application for market approval of injection Rituximab accepted and included in priority review process.

CR ASIA (00831) announces profit growth is expected to increase by more than 40% annually for the 2025 fiscal year.

JINKE SERVICES (09666) spent HK$3.3741 million on February 10 to repurchase 38,830 shares.
Jiangsu Hengrui Pharmaceuticals (01276): Application for market approval of injection Rituximab accepted and included in priority review process.

CR ASIA (00831) announces profit growth is expected to increase by more than 40% annually for the 2025 fiscal year.

JINKE SERVICES (09666) spent HK$3.3741 million on February 10 to repurchase 38,830 shares.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


